Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...

Now Neurocrine Bioscience, with Ingrezza and elagolix not far behind it, could become a significant mid-size company within just a few years. Andrew McConaghie 11 April, 2017 ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said it presented positive data from Phase 3 KINECT-HD study evaluating Ingrezza capsule in adults with Huntington's disease at the ...

In analyst updates, RBC Capital Markets revised its price target for Neurocrine Biosciences to $139, down from $148, due to increased restrictions on Ingrezza, a key product. Deutsche Bank has ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

Neurocrine Biosciences ... The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...